FY2025 EPS Estimate for Esperion Therapeutics Cut by Analyst

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities researchers at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for shares of Esperion Therapeutics in a research report issued on Wednesday, May 7th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biopharmaceutical company will post earnings of $0.09 per share for the year, down from their prior estimate of $0.12. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share.

Several other analysts also recently issued reports on the company. JMP Securities reissued a “market outperform” rating and set a $4.00 target price (down previously from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. The Goldman Sachs Group lowered their target price on shares of Esperion Therapeutics from $4.00 to $3.00 and set a “neutral” rating on the stock in a report on Thursday, April 17th. Needham & Company LLC cut their target price on shares of Esperion Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research note on Friday, April 25th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Esperion Therapeutics currently has an average rating of “Hold” and a consensus price target of $6.25.

Esperion Therapeutics Stock Performance

Shares of ESPR stock opened at $0.80 on Friday. The stock has a fifty day simple moving average of $1.24 and a two-hundred day simple moving average of $1.88. Esperion Therapeutics has a 52-week low of $0.73 and a 52-week high of $3.94. The firm has a market capitalization of $158.16 million, a PE ratio of -1.25 and a beta of 0.75.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). The business had revenue of $65.00 million for the quarter, compared to analyst estimates of $54.97 million.

Hedge Funds Weigh In On Esperion Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Wasatch Advisors LP raised its holdings in Esperion Therapeutics by 4.9% during the 4th quarter. Wasatch Advisors LP now owns 24,482,258 shares of the biopharmaceutical company’s stock valued at $53,861,000 after buying an additional 1,136,245 shares during the period. Two Sigma Advisers LP grew its holdings in Esperion Therapeutics by 0.4% during the 4th quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company’s stock valued at $7,956,000 after purchasing an additional 16,100 shares during the last quarter. Nuveen Asset Management LLC raised its position in Esperion Therapeutics by 48.6% in the 4th quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company’s stock worth $6,862,000 after purchasing an additional 1,020,243 shares during the period. JPMorgan Chase & Co. lifted its stake in Esperion Therapeutics by 18.6% in the fourth quarter. JPMorgan Chase & Co. now owns 2,454,216 shares of the biopharmaceutical company’s stock worth $5,399,000 after purchasing an additional 385,099 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Esperion Therapeutics by 45.1% during the fourth quarter. Bank of America Corp DE now owns 1,629,980 shares of the biopharmaceutical company’s stock valued at $3,586,000 after buying an additional 506,428 shares during the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.